Search results for " cost-benefit analysis"

showing 10 items of 13 documents

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Preventing and managing herpes zoster: key actions to foster healthy aging

2015

Population aging is the demographic phenomenon characterizing all countries in the world, and it is challenging the national infrastructures, in particular health systems. However, aging itself is not associated with increased medical spending, but disability and comorbidity that affect older individuals are the actual drivers for health expenditures. Therefore, if people age in better health, medical spending may be significantly reduced. Preventative interventions proved to be effective in reducing/preventing disease and disability and often found to be cost effective, include diet and exercise interventions, medications, routine disease screenings, and immunizations. Vaccination can prot…

Gerontologymedicine.medical_specialtyPopulation ageingAgingSettore MED/17 - Malattie InfettiveImmunosenescenceCost-Benefit AnalysisHerpes zosterAlternative medicinePsychological interventionSocio-culturaleDiseaseSettore MED/42 - Igiene Generale E ApplicataQuality of life (healthcare)medicineHerpes Zoster VaccineHumansHerpes zoster; Immunosenescence; Vaccine; Aged; Cost-Benefit Analysis; Herpes Zoster; Herpes Zoster Vaccine; Humans; Italy; Middle Aged; Quality of Life; Aging; Vaccination; Aging; Geriatrics and GerontologyAgedbusiness.industryTetanusVaccinationHerpes zoster; Immunosenescence; Vaccine; Aging; Geriatrics and GerontologyMiddle Agedmedicine.diseaseComorbidityVaccinationItalyQuality of LifeGeriatrics and GerontologybusinessVaccineVaccine; Herpes zoster;Immunosenescence
researchProduct

Implementation of the eHealth Project in Latvia: Project audit perspective

2016

In order to improve effectiveness of provision of healthcare service, the project implemented by the Ministry of Health- ”E-health in Latvia” is a step towards the right direction. It will provide the possibility for patients to ensure a greater control over their health issues, by maintaining healthy habits, lifestyle, increase substantiation of adoption of decisions and speed of service in the healthcare industry, ensuring quality and accessible information; patients will receive more quality services and in a shorter period of time for issuance of prescription drugs. Nevertheless, the policy prepared by the Ministry of Health in the area of e-Health will not be implemented in the planned…

H43 - Project Evaluation ; Social Discount RateD6 - Welfare EconomicsD61 - Allocative Efficiency ; Cost-Benefit AnalysisO22 - Project Analysis
researchProduct

New development opportunities for the craft brewing segment: the case study of a micro-malthouse

2017

In Italy in the past few years, the number of small breweries penetrating the craft beer sector has grown exponentially. Craft producers intend to give a strong added value and a local character to their production in different ways. One of these is the use of malt derived from small batches of local cereals and pseudo cereals. The aim of this study is the assessment of investment profitability, through a cost-benefit analysis (CBA), for a compact and a modular micro-malting plant in Sicily (Southern Italy). The CBA for a micro-malthouse was carried out considering both installation and operating costs. Net present value (NPV), discounted benefit-cost ratio (DBCR) and internal rate of retur…

Internal areasInformation Systems and Managementinternal areas.Management Science and Operations ResearchNet present valueCBA; Cereal processing; Cost-benefit analysis; Internal areas; Malting; Malting plant; SicilyCraftAgricultural scienceSettore AGR/01 - Economia Ed Estimo RuraleAdded valueProduction (economics)maltingBusiness and International ManagementSicilybusiness.industryCost-benefit analysisInternal rate of returnSettore AGR/15 - Scienze E Tecnologie AlimentariInvestment (macroeconomics)malting plantcereal processingcost–benefit analysiBrewingProfitability indexbusinessCBA
researchProduct

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

2016

In Italy, the Italian Pharmaceutical Agency (AIFA) criteria used F3–F4 fibrosis stages as the threshold to prioritise the treatment with interferon (IFN)-free regimens, while in genotype 1 chronic hepatitis C (G1 CHC) patients with fibrosis of liver stage 2, an approach with pegylated interferon (PEG-IFN)-based triple therapy with simeprevir was suggested. The key clinical question is whether, in an era of financial constraints, the application of a universal IFN-free strategy in naive G1 CHC patients is feasible within a short time horizon. The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing hepatitis C…

Liver CirrhosisSimeprevirmedicine.medical_specialtyCost-Benefit AnalysisPopulationAntiviral Agents03 medical and health sciencesIndirect costs0302 clinical medicineAntiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome; Pharmacology (medical)SimeprevirRibavirinmedicineHumansPharmacology (medical)030212 general & internal medicineChronicIntensive care medicineeducationReimbursementeducation.field_of_studyCost–benefit analysisbusiness.industryHealth services researchGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CMarkov ChainsQuality-adjusted life yearTreatment OutcomeItalyDisease Progression030211 gastroenterology & hepatologyInterferonsQuality-Adjusted Life YearsbusinessMonte Carlo MethodClinical Drug Investigation
researchProduct

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

2013

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for …

MaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCost effectivenessCost-Benefit AnalysisSettore MED/12 - GASTROENTEROLOGIAAged; Antineoplastic Agents; Carcinoma Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life YearsAntineoplastic AgentsKaplan-Meier EstimateDrug CostsInternal medicinemedicineHumansProspective StudiesProspective cohort studyneoplasmsSurvival rateAgedHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsCarcinomaHepatocellular carcinoma sorafenib ICER cost-effectivenessHepatocellularSorafenibmedicine.diseaseMarkov Chainsdigestive system diseasesSurgeryQuality-adjusted life yearHepatocellular carcinomaMultivariate AnalysisQuality-Adjusted Life YearsbusinessLiver cancermedicine.drugHepatology
researchProduct

Economic and Financial Comparison between Organic and Conventional Farming in Sicilian Lemon Orchards

2015

Sicily has a long tradition in citrus fruit cultivations that with vineyard and olive tree represent the main Mediterranean tree crops. In this paper we have evaluated the economic and financial sustainability of lemon production, both in organic farming and in conventional farming

Organic productlemonlcsh:TJ807-830Geography Planning and Developmentlcsh:Renewable energy sourcesEcological farmingagricultural practicesManagement Monitoring Policy and Lawcost-benefit analysiAgricultural scienceorganic farmingjel:QSettore AGR/01 - Economia Ed Estimo Ruraleagricultural practices; cost-benefit analysis; lemon; organic farming; profitabilityEconomicsNatural farmingprofitabilitylcsh:Environmental scienceslcsh:GE1-350Renewable Energy Sustainability and the EnvironmentAgroforestryIntensive farmingcost-benefit analysislcsh:Environmental effects of industries and plantsjel:Q0jel:Q2jel:Q3jel:Q5lcsh:TD194-195agricultural practiceIntensive crop farmingjel:O13Extensive farmingOrganic farmingjel:Q56Mixed farmingSustainability
researchProduct

Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma.

2009

Background The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice. Objective To compare the different economic relevance, over a long evaluation time, of symptomatic pharmacologic therapy and sublingual immunotherapy (SLIT) in patients with allergic asthma. Methods Seventy patients with perennial allergic asthma, sensitized to dust mites, were enrolled; 50 of these patients were treated with SLIT against house dust mites and 20 were treated with symptomatic drugs. The patients were evaluated for …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyAdolescentCost-Benefit AnalysisImmunologyPopulationAdministration SublingualFollow-Up StudieSublingual administrationDrug TherapyImmunopathologyInternal medicinemedicineImmunology and AllergyHumansCost-Benefit AnalysieducationChildAsthmaeducation.field_of_studyDrug Therapy; Combined Modality Therapy; Immunotherapy; Humans; Asthma; Child; Health Care Costs; Cost-Benefit Analysis; Adult; Middle Aged; Follow-Up Studies; Adolescent; Administration Sublingual; Male; Femalebusiness.industryRespiratory diseaseHealth Care CostsMiddle Agedmedicine.diseaseSlitCombined Modality TherapyAsthmaSurgeryHealth Care CostObservational studyFemaleImmunotherapybusinessHumanFollow-Up StudiesAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Evaluating Infrastructure Alternatives for Regional Water Supply Systems by Model-assisted Cost-benefit Analysis – A Case Study from Apulia, Italy

2014

The main challenge associated to regional water supply systems planning lies in understanding the best infrastructure alternatives to improve service given a certain configuration of the resources system. While cost-effectiveness assessments are still widespread in this type of analyses, they do not account for the fact that, especially in mature systems, service improvements tend to follow the law of marginal diminishing returns, so that a cost – benefit assessment should be preferable. Both costs and benefits can be organized into a cost-benefit analysis (CBA) framework. In a complex system, a model reproducing its topology and characteristics better describes the impacts of the alternati…

Service (systems architecture)EngineeringCost–benefit analysisbusiness.industryCost-Benefit AnalysisSettore ICAR/02 - Costruzioni Idrauliche E Marittime E IdrologiaWater supplyTopology (electrical circuits)General MedicineReliability ;computer.software_genreSimulation softwareRegional water supply systemsinfrastructure alternatives regional water supply systems model-assisted cost-benefit analysisRisk analysis (engineering)Work (electrical)businesscomputerSimulationEngineering(all)Procedia Engineering
researchProduct